King touched on the three oral JAK inhibitors that are currently commercially available, and discussed how they have been used in recent trials and studies to treat alopecia areata, vitiligo, and AD. Xeljanz (tofacitinib): FDA-approved for rheumatoid and psoriatic arthritis.